Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Patent Number: 7,211,600
Date of First Priority Issue: Wednesday December 22nd, 1999
Date Issued: Tuesday May 1st, 2007
Assignee: Sugen Inc. (South San Francisco, CA)
Inventors: Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
From Class: Expansion
Comments: No comments
It is known that tumor stem cells share many properties with non-malignant stem cells, such as expression of CD133. The receptor for stem cell factor, c-kit, is found on numerous types of normal stem cells in addition to hematopoietic stem cells, where it was originally discovered.
This current patent discloses a variety of compounds that inhibit activity of the c-kit kinase. The compounds are indolinone derivatives and are claimed for activity against gastrointestinal tumors, mastocytomas, allergy-associated chronic rhinitis, inflammation or asthma.
View this patent on the USPTO website.
Added to StemCellPatents.com on Saturday May 5th, 2007
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.